Histamine H3 receptor function and ligands: Recent developments

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 47-57

  Singh, Mahaveer ^a   Jadhav, Hemant R ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Epilepsy; Obesity

Indexed keywords

4 AMINOBUTYRIC ACID; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; A 317920; A 331440; A 417022; A 687136; ACETYLCHOLINE; AQ0145; CARISBAMATE; CIPRALISANT; CIPROXIFAN; CLOBENPROPIT; FUB 181; FUB 836; GSK 1; GSK 207040; GSK 239512; GSK 334429; GT 2227; GT2016; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; IMETIT; JB 98064; JNJ 10181457; JNJ 17216498; JNJ 5207852; JNJ 7737782; LIGAND; MEPYRAMINE; MK0249; PF 03654746; QUINOLINE DERIVATIVE; RWJ 20085; SEROTONIN; THIOPERAMIDE; UNCLASSIFIED DRUG; VUF 5391; HISTAMINE H3 RECEPTOR ANTAGONIST;

ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; COGNITION; EPILEPSY; HUMAN; MEMORY; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; SEIZURE; SLEEP; WAKEFULNESS; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; METABOLISM; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HISTAMINE H3 ANTAGONISTS; HUMANS; LIGANDS; RECEPTORS, HISTAMINE H3;

EID: 84875015118     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804484695     Document Type: Article

References (113)

1. 3)of histamine receptor. Nature, 1983, 302, 832-837.
2. Brown, R.E.; Stevens, D.R.; Hass, H.L. The physiology of brain histamine. Prog. Neurobiol., 2001, 63, 637-672.
3. Hass, H.; Panula, P. The role of histamine and tuberomamillary nucleus in the central nervous system. Nat. Rev. Neurosci., 2003, 4, 121-130.
4. Kazumori, H.; Ishihara, S.; Rumi, M.A.; Ortegacava, C.F.; Kadowaki, Y.; Kinoshita Y. Transforming growth factor-alpha directly augments histidine decarboxylase and vesicular monoamine transporter 2production in rat enterochromaffin like cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286, 508-514.
5. 2receptor antagonist. New Eng. J. Med., 1983, 309, 1368-1373.
6. 3receptor antagonists go to clinics. Biol. Pharm. Bull., 2008, 12, 2163-2181.
7. Morisset S.; Rouleau, A.; Ligneau, X.; Gbahou, F.; Tardivel-Lacombe, J.; Stark, H.; Schunack, W.; Ganellin, CR.; Schwartz, JW.; JM. High constitutive activity of native H-3 receptors regulates histamine neurons in brain. Nature, 2000, 408, 860-864.
8. 3receptors as drug discovery target. J. Med. Chem., 2011, 54,1-27.
9. Yokoyama, H.; Linuma, K. Studies and functional role of histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography. CNS Drugs, 1996, 5, 321-330.
10. Hass, H.L.; Sergeeva, O.A.; Selbach, O. Histamine in nervous system. Physiol. Rev., 2008, 88, 1183-1241.
11. 3receptor. Mol. Pharmacol., 1999, 55, 1101-1107.
12. 3receptor heterogenecity. Life Sci., 2003, 55, 1101-1107.
13. 3receptor. Biochem. Pharmcol., 2007, 73, 1195-1204.
14. 3receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther., 2000, 293, 1177-1178.
15. 3autoreceptor modulate histamine synthesis through cAMP pathway. Mol. Pharmacol., 2002, 61, 239-245.
16. Churchill, J.A.; Gammon, G.D. The effect of antihistaminic drugs on convulsive seizure. Am. Med. Assoc., 1949, 141, 18-21.
17. Tuomisto L.; Tacke U. 2-thiozolylethylamine, a seelective histamine H1 agonist decrease seizure susceptibility in mice. Neuropharmacology, 1986, 25, 955-958.
18. 3Receptors. Ph.D. Thesis, The University of Regenburg: Germany, December 2009.
19. 1receptor. J. Pharmacol. Exp. Ther., 2008, 326, 783-791.
20. Midzyanovskaya, I. S.; Tuomisto, L. Increased density of H1 histamine receptors in brain regions of rats with absence epilepsy. Inflamm. Res., 2003, 52, S29-S30.
21. Yokoyama, H; Iinuma, K; Yanai, K; Watanabe, T; Sakurai, E; Onodera, K. Proconvulsant effect of ketotifen, a histamine H1antagonist, confirmed by the use of D-chlorpheniramine with monitoring electroencephalography. Meth. Find Exp. Clin. Pharmacol., 1993, 15, 183-188.
22. Vohora, D.; Pal, S.N.; Pillai, K.K. Histamine as an anticonvulsant inhibitory neurotransmitter. Curr. Neuropharmacol., 2004, 2, 419-425.
23. 3receptor antagonist, on electrically induced convulsions in mice. Eur. J. Pharmacol. 1993, 234, 129-133.
24. 3receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther., 2004, 103, 1-20.
25. 3antagonist with carbonyl substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compound. J. Med. Chem., 2000, 43, 3987-3994.
26. 3-receptors as modulators of CNS function. Ind. J. Pharmacol., 2001, 33, 17-28.
27. 3antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology, 2006, 50, 404-411.
28. 1receptor dependant release of g-aminobutyric acid from rat striatal slices. Br. J. Pharmacol., 2001, 133, 165-171.
29. Korotkova, T.M.; Hass, H.L.; Brown, R.E., Histamine Excites GABAergic cells in rat substantia nigra and ventral tegmental area in vitro. Neurosci. Lett., 2002, 320, 133-136.
30. Bergquist, F.; Rut, J.A.; Hven, A.; Ludwig, M.; Dutia, M.B. Histaminergic and glycinergic modulation of GABA release in the vestibular in the nuclei of normal and labyrinthectomised rats. J. Physiol., 2006, 577, 857-868.
31. Mclaughlin, F. L. Actylcholine in treatment of epilepsy. Br. Med. J., 1933, 1, 997-998.
32. 3receptor-mediated impairment of contextual fear conditioning, and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur. J. Neurosci., 2001, 14, 1522-1532.
33. Cecchi, M.; Giorgetti, M.; Bacciottini, L.; Giovannini, M. G.; Blandina, P. The role of Interactions between histaminergic and cholinergic systems in learning and memory. Inflamm. Res., 1998, 47, S32-S33.
34. Philippu, A.; Prast, H. Importance of histamine in modulatory processes, locomotion and memory. Behav. Brain Res., 2001, 124, 151-159.
35. Kraus, M. M.; Fischer, H.; Tran, M. H.; Philippu, A.; Prast H., Modulation of acetylcholine release by histamine in the nucleus accumbens. Inflamm. Res., 2001, 50, S74-S75.
36. Fink, K.; Schlicker, E.; Neise, A.; Gothert, M. Involvement of Presynaptic receptors in inhibitor effect of histamine on serotonin release in rat brain cortex. Arch. Pharmacol., 2008, 342, 513-519.
37. 3receptor inhibits serotonin release in substantia nigra pars reticulate. J. Neurosci., 2004, 24, 8704-8710.
38. Tokita, S.; Takahashi, K.; Kotani, H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharmacol. Sci., 2006, 101, 12-18.
39. Masaki, T.; Yoshimatsu H., Neuronal histamine and its receptors in obesity and diabetes Curr. Diabetes Rev., 2007, 3, 212-216.
40. 3receptors in rat brain areas. Neuroscience, 1993, 52, 169-189.
41. Masaki, T.; Yoshimatsu, H.; Chiba, S.; Watanabe, T.; Sakata, T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin resistant obese mice. Diabetes, 2001, 50, 376-384.
42. Matsui-Sakata, A.; Ohtani, H.; Sawada, Y. Receptor occupancy based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab. Pharmacokinet., 2005, 20, 368-378.
43. Orgensen, E.A.; Knigge, U.; Warberg, J.; Kjaer, A. Histamine and the regulation of body weight. Neuroendocrinology, 2007, 86, 210-214.
44. 1receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol. Sci., 2006, 27, 279-284.
45. Machidori, H; Sakata, T; Yoshimatsu, H.; Wada, H. Zucker obese rats: defect in brain histamine control on feeding. Brain Res., 1992, 590, 180-186.
46. 3receptor on sleep and wakefulness. Eur. J. Pharmacol., 1991, 205, 283-287.
47. Jones, B. E. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol. Sci., 2005, 26, 578-586.
48. Parmentier, R.; Ohtsu, H.; Djebbara-Hannas, Z.; Valatx, J.L.; Watanabe, T.; Lin, J.S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci., 2002, 22, 7695-7711.
49. 3receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J. Pharmacol. Exp. Ther., 1998, 287, 43-50.
50. Kiyono, S.; Seo, M.L.; Shibagaki, M; Watanabe, T.; Maeyama, K.; Wada, H. Effects of alpha-fluoromethyl histidine on sleep-waking parameters in rats. Physiol. Behav., 1985, 34, 615-617.
51. Lamberty, Y.; Margineanu, D.G.; Dassesse, D.; Klitgaard, H. H3 agonist immepip markedly reduces cortical histamine release, but only weakly promotes sleep in the rat. Pharmacol. Res., 2003, 48, 193-198.
52. Le, S.; Gruner, J.A.; Mathiasen, J.R.; Marino, M.J.; Schaffhauser, H. Correlation between ex vivo receptor occupancy and wakepromoting activity of selective H3 receptor antagonists. J. Pharmacol. Exp. Ther., 2007, 325, 902-909.
53. Mercier, V.G.; Sakai, K.; Jouvet, M. Specific neurons for wakefulness in the posterior hypothalamus in the cat. C. R. Acad. Sci., 1984, 298,195-200.
54. Mochizuki, T.; Okakura-Mochizuki, K.; Horii, A.; Yamamoto, Y.; Yamatodani, A. Histaminergic modulation of hippocampal acetylcholine release in vivo. J. Neurochem., 1994, 62, 2275-2282.
55. Haas, H; Panula, P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci., 2003, 4, 121-130.
56. Panula, P.; Rinne, J.; Kuokkanen, K.; Eriksson, K.S.; Sallmen, T.; Kalimo, H.; Relja, M. Neuronal histamine deficit in Alzheimer's disease. Neuroscience, 1998, 82, 993-7.
57. 1receptor antagonist-induced spatial memory deficits in rats. Eur. J. Pharmacol., 2001, 423, 167-170.
58. Mochizuki, T.; Okakura, M.K.; Horii, A.; Yamamoto, Y.; Yamatodoni, A. Histaminergic modulation of hippocampal acetylcholine release in vivo. J. Neurochem., 1994, 62, 2275-2282.
59. 3antagonist, on the step through passive avoidance response and histidine decarboxylase activity in senescence accelerated mice. Pharmacol. Biochem. Behav., 1995, 50, 321-325.
60. 3receptor modulation in the septum on post-training memory processing. Psychopharmacology, 1998, 140, 279-84.
61. Miyazaki, S.; Imaijumi, M.; Onodera, K. Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice. Methods Find. Exp. Clin. Pharmacol., 1995, 17, 653-658.
62. Orsetti, M.; Ghi, P.; Di Carlo, G. Histamine H(3)-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task. Brain Res., 2001, 124, 235-242.
63. Oades, R.D. Attention deficit disorder with hyperactivity (ADDH): contribution of catecholaminergic activity. Prog. Neurobiol., 1987, 29, 365-391.
64. Dumery, V.; Blozovski, D. Development of amygdaloid cholinergic mediation of passive avoidance learning in the rat., Exp. Brain Res., 1987, 67, 61-69.
65. Biederman, J.; Spencer, T. Attention-deficit hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry., 1999, 46, 1234-1242.
66. Leurs, R.; Vollinga, R.C.; Timmerman, H. Medicinal chemistry and theraputic potential of ligands of histamine H-3 receptors. Prog. Drug. Res., 1995, 45, 107-165.
67. 3antagonist. Drugs Future, 1996, 21, 507-520.
68. 3receptor agonists. Mini Rev. Med. Chem., 2004, 4, 955-963.
69. 3receptor antagonist reach out for the clinics. Drug Disc. Today, 2005, 10, 1613-1627.
70. 3-receptor antagonists., Eur. J. Pharm. Sci., 2001, 13, 249-259.
71. 3receptor agonist., J. Pharmacol. Exp. Ther., 1992, 263, 304-310.
72. 3receptor antagonist., J. Pharmacol. Exp. Ther., 1998, 287, 658-666
73. Arrang, J.M.; Garbarg, M.; Lancelot, J.C.; Lecomte, J.M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J. C. Highly potent and selective ligands for histamine receptors. Nature, 1987, 327, 117-123.
74. 3receptor. Eur. J. Med. Chem., 1992, 27, 511-517.
75. 3receptor antagonist go to the clinics. Biol. Pharm. Bull., 2008, 12, 2163-2181.
76. 3receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem. 2001, 44, 1666-1674.
77. 3receptor antagonists reach out for the clinic. Drug Disc. Today, 2005, 10, 1613-1627.
78. Frank U. A.; Scott D.; Sandor S. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J. Mol. Gr. Mod., 2006, 24, 456-464.
79. 3antagonists. Mini Rev. Med. Chem., 2004, 4, 979-992.
80. 3receptor drugs. Nat. Rev. Drug Discovery, 2005, 4, 107-120.
81. 3receptor antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 3309-3312.
82. 3receptor antagonists: from target identification to drug leads. Biochem. Pharmacol., 2007, 73, 1084-1096.
83. 3antagonist. Br. J. Pharmacol., 2004, 143, 649-661.
84. Galici, R.; Boggs, J.D.; Aluisio, L.; Fraser, I.C.; Bonaventure, P.; Lord, B.; Lovenberg, T.W. JNJ-10181457, a selective nonimidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology, 2009, 56, 1131-1137.
85. A safety and effectiveness study of a single dose of JNJ-17216498 in patients with narcolepsy. http://www.clinicaltrials.gov/ct2/show/ NCT00424931?intr="JNJ-17216498"&rank=1 (Accessed December 18, 2011)
86. Safety and Efficacy of RWJ-333369 in the Treatment of Partial Epilepsy. http://www.clinicaltrials.gov/ct2/show/NCT00228969? term=RWJ&rank=14 (Accessed December 19, 2011)
87. Tedford, C.E.; Yates, S.L.; Pawlowski, G.P.; Nalwalk, J.W.; Hough, L.B.; Amin, K. M.; Phillips, J.G.; Durant, G.J.; Frederickson, R.C.A. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies. J. Pharmacol. Exp. Ther., 1995, 275, 598-604.
88. 3-receptor agonists and antagonists: chemical, pharmacological, and clinical aspects. Chem. Mol. Aspects Drug Des. Action, 2008, 199, 199-214.
89. 3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure., Arch. Pharm., 1998, 331, 211-218.
90. 3receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin. Invest. Drugs, 2007, 16, 967-985.
91. 3receptor: Preclinical pharmacology. J. Pharmacol. Exp. Ther., 2007, 320, 365-375.
92. 3antagonist. Bioorg. Med. Chem. Lett., 2002, 12, 3055-3058.
93. 3receptor ligands with combined inhibitory histamine N-methyltransferase activity. J. Med. Chem., 2002, 45, 1128-1141.
94. 3receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther., 2003, 305, 897-908.
95. 3receptor antagonist. Biochem. Pharmacol., 2004, 68, 933-945.
96. 3receptor antagonist. Eur. J. Pharmacol., 2004, 487, 183-197.
97. 3antagonist ABT-239. Tetrahedron Lett., 2006, 62, 4584-4589.
98. 3receptor ligands. Part Binding preference for D-amino acids motifs. Bioorg. Med. Chem. Lett., 2002, 12, 2035-2037.
99. 3receptor antagonists potently enhance cognition and attention. J. Med. Chem. 2005, 48, 38-55.
100. 3receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem. Pharmacol., 2007, 73, 1243-1255.
101. 3antagonist. Org. Process Res. Dev., 2007, 11, 1004-1009.
102. 3receptor antagonists. J. Med. Chem., 2008, 51, 5423-5430.
103. 3receptor inverse agonists. J. Med. Chem,. 2007, 50, 5439-5448.
104. 3antagonists. Ann. Rep. Med. Chem., 2007, 42, 49-62.
105. 3receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther., 2007, 321, 1032-1045.
106. 3receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem. Pharmacol., 2007, 73, 1182-1194.
107. Bridging Study with GSK239512 in patients with mild to moderate Alzheimer's disease. http://www.clinicaltrials.gov/ct2/ show/NCT00675090?term=GSK-239512&rank=1 (Accessed December 19, 2011)
108. 3receptor antagonist GSK207040. Psychopharmacology, 2009, 201, 483-494.
109. 3receptor inverse agonists. J. Med. Chem., 2008, 51, 4780-4789.
110. 3receptor inverse agonists. J. Med. Chem., 2008, 51, 6889-6901.
111. Nagase, T.; Sato, N.; Kii, S.; Sato, K.; Tsuritani, T.; Sawada, N. Process for Production of 4(3H)-Quinazolinone Derivative. PCT Int. Appl., 2006, (E-pub ahead of print).
112. 3receptor inverse agonists. Bioorg. Med. Chem. Lett., 2008, 18, 6041-6045.
113. A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults with Attention Deficit Hyperactivity Disorder (ADHD). http://www.clinicaltrials.gov/ct2/show/ NCT00531752?term=PF-03654746&rank=1 (Accessed December 19, 2011).